Researchers at Voronoi Bio Inc. and Voronoi Inc. have disclosed receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors reported to be useful for the treatment of cancer, inflammatory bowel disease, psoriasis, rheumatoid arthritis, myocardial infarction, Alzheimer's disease, asthma and type 1 diabetes, among others.
The HIV-1 envelope glycoprotein (Env) mediates cell entry and is the target of the host humoral immune response. Functional Env is a trimer of noncovalent gp120-gp41 heterodimers. Rational trimer design has transformed the HIV-1 vaccine research field and has helped understand Env structure and immunogenicity. Uncleaved prefusion-optimized (UFO) trimers have been shown to stabilize diverse HIV-1 Env glycoproteins.
Bayer AG’s diacylglycerol kinase ζ (DGK-ζ) inhibitor BAY-2965501 is being developed as a first-in-class cancer immunotherapy candidate. The company recently presented preclinical data on the compound, which supported advancement of the candidate into clinical testing, with a first-in-human phase I study in solid tumors underway (NCT05614102).
Osteosarcoma (OS) is an aggressive cancer type, with frequent metastasis seen in the lungs, and for which two-thirds of metastatic patients fail to achieve durable responses and die due to the disease.
Rona Therapeutics Inc. and Keymed Biosciences Co. Ltd. have established a collaboration to jointly discover and develop first-in-class siRNA therapeutics for glomerulonephritis. The collaboration will leverage both companies’ scientific and technological expertise and will build on Rona’s proprietary platform in RNAi targeting liver and extrahepatic tissues.
Researchers from Byondis BV and Sanquin Bloedvoorziening have published preclinical data on a new signal-regulatory protein α (SIRPα)-directed antibody, BYON-4228.
Dualyx NV has completed a €40 million (US$44 million) series A financing, allowing the company to advance its lead autoimmune program, DT-001, as well as its pipeline of regulatory T-cell (Treg) candidates.
A new study has discovered a promising approach to improve the efficacy of adoptive cell therapies for cancer. The research, published in Molecular Therapy: Nucleic Acids, describes the development of novel Fas-TNFR chimeras acting as decoys for the Fas ligand and preventing it from binding to its natural receptor on the surface of chimeric antigen receptor (CAR) T cells.
TRPV3 is a temperature-sensitive transient receptor potential (TRP) ion channel that functions as a regulator of skin homeostasis. The epidermal overexpression of TRPV3 is linked to dermatological conditions with increased inflammation signals such as dermatitis, hyperkeratosis, keratoderma or pruritus.
Acesion Pharma ApS has announced promising data from preclinical studies with AP-31969, its second-generation oral SK channel inhibitor developed for chronic oral maintenance treatment to prevent atrial fibrillation (AF) recurrence. Acesion aims to develop a novel drug for AF that solves the risk of proarrhythmia associated with existing drugs.
RSS
